Breaking News: Local biotech's Duchenne gene therapy wins expanded FDA approval

The FDA has expanded its previous approval for a local biotech's gene therapy to treat Duchenne muscular dystrophy — but the agency didn't go quite as far in its approval as the company had hoped. $SRPT The FDA has expanded its previous approval for a local biotech's gene therapy to treat Duchenne muscular dystrophy — but the agency didn't go quite as far in its approval as the company had hoped. $SRPT [Boston Business Journal]( June 20, 2024 Breaking News [Sarepta’s Duchenne gene therapy wins partial FDA approval]( The FDA has expanded its previous approval for a local biotech's gene therapy to treat Duchenne muscular dystrophy — but the agency didn't go quite as far in its approval as the company had hoped. $SRPT [Read Full Article]( Related News [Make-or-break decision on Cambridge biotech's drug expected this week]( [Major Boston biotech begins layoffs this week]( [Ed Kaye is chasing yet another rare-disease drug for ailing kids]( [Drug watchdog criticizes Sarepta gene therapy approval, cost]( [Ultragenyx to open gene-therapy R&D HQ in Mass.]( [View as a Web Page]( [Unsubscribe]( | [Manage Preferences]( All rights reserved. © Boston Business Journal Email sent by Boston Business Journal 70 Franklin Street, 8th Floor Boston, MA 02110 USA